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COBRA PzF Coronary StentBecause of anticipated antiplatelet medication risks, patients who are not DES candidates or who are at particu-
larly high risk for bleeding events have been targeted initially for treatment with the COBRA PzF Coronary Stent
System.We report the case of a successful experiencewith a new, Polyzene™-F COBRA PzF™ Coronary Stent Sys-
tem, designed to impart thrombo-resistance and reduce inﬂammation, to achieve shorter dual antiplatelet ther-
apy duration while reducing restenosis incidence in a high risk patient with atrial ﬁbrillation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Evenwith the use of new-generation drug-eluting stents (DES), stent
thrombosis and major adverse cardiac and cerebrovascular events
(MACCE; composite of death, myocardial infarction or stroke) continue
to be clinical risks associated with coronary stent placement. Mitigation
of these risks is accomplished with consideration of the patient's comor-
bidities and stent selection. Typically, stent choice requires pharmacolog-
ic antiplatelet medication for a minimum of 1 month of dual antiplatelet
therapy (DAPT; combination of ASA and a P2Y12 inhibitor) post bare
metal stent (BMS) placement or for a minimum of 6–12 months DAPT
after placement of a drug-eluting stent (DES) per ACCF/AHA/SCAI 2011
PCI and ESC/EACTS 2014 Guidelines on elective percutaneous coronary
intervention (PCI) [1,2,3].
Patients treated for atrial ﬁbrillation (AF) are at additional riskwhen
undergoing PCI. Combining chronic oral anticoagulation (OAC) therapy
with DAPT, resulting in triple antithrombotic therapy, has been and con-
tinues to be intensely scrutinized. Prevention of thromboembolic
(stroke) and atherothrombotic (stent thrombosis) events is balanced
against the increase risk of severe bleeding in all, but in particular, the
triple therapy patients [4]. Careful deliberation includes reducing the
duration of or eliminating one or more antithrombotic medications asl stent; DAPT, dual antiplatelet
e cardiac and cerebrovascular
on; PCI, percutaneous coronary
ngioplasty.
D have no relevant conﬂicts of
Isarkanal 30, D-81379 Munich,
. This is an open access article underwell as consideration of alternative stent designs for patients at higher
risk of bleeding events.
Amiddle ground in stent design, available through use of Polyzene™-F
nano-coating, is designed to impart thrombo-resistance and reduce in-situ
inﬂammation. This coating on the COBRA PzF™ Coronary Stent System of-
fers a compromise position by shortening DAPT duration to one month
with the potential of reducing restenosis incidence. Patients who are not
DES candidates or who are at higher risk for bleeding events have been
targeted initially for treatmentwith the COBRA PzF Coronary Stent System
and this report provides a description of one of the ﬁrst uses of the device
system with its special properties.2. Case report
A 72-year-old female with a history of signiﬁcant comorbidities, in-
cluding atrial ﬁbrillation, angina (CCS III), arterial hypertension, heart
failure, hyperlipidemia, diabetes mellitus type 2 and history of ischemic
stroke, was diagnosed with a 75% stenotic mid-LAD lesion; see Fig. 1.
Additional risk assessments included a CHA2DS2-VASc score of 7,
which is associated with a 9.6% per year risk of stroke without warfarin
treatment [5,6], and a HAS-BLED score of 4, which is associated with a
4.9%–19.6% one year bleeding risk while on oral anticoagulants [7].
This particular subject's speciﬁc, but not atypical, proﬁle places her at
signiﬁcant bleeding risk so appropriate stent selection was critical. In
April 2014, she received a cobalt chromium alloy COBRA PzF Stent
with Polyzene™-F nano-coating (CeloNova BioSciences, Inc., San
Antonio, Texas). The COBRA PzF Stent (CE marked) is indicated for im-
proving coronary luminal diameter in patients with symptomatic ische-
mic heart disease due to coronary artery lesions and is intended for use
in patients eligible for percutaneous transluminal coronary angioplasty
(PTCA, PCI) with reference vessel diameter of 2.5–4.0 mm.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Baseline image is depicted of a 75% stenotic mid-LAD lesion in a female with multi-
ple co-morbidities, including atrial ﬁbrillation, arterial hypertension, heart failure, hyper-
lipidemia, diabetes mellitus type 2 and history of ischemic stroke.
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proﬁle, due in part to the thin (71 μm) struts, the COBRA PzF stent
proved its deliverability. Stent delivery and deployment were unre-
markable and the stent's radiopacity permitted an appreciation of full
apposition within the target vessel; see Fig. 2.
2.1. Medical therapy
Post-procedure antiplatelet therapy consisted of clopidogrel (75 mg)
and acetylsalicylic acid (100 mg) daily for 4 weeks. Due to atrial ﬁbrilla-
tion, phenprocoumon, a coumarin vitamin K antagonist, was adminis-
tered, targeting an INR of 2.0–2.5, during the same 4 week period, after
which rivaroxaban (20 mg), a direct factor Xa inhibitor, was prescribed
daily. Themodiﬁcation in anticoagulation regimen from phenprocoumon
to rivaroxaban after 4 weeks was made on the patients' desire to avoid
INR controls and require as few tablets as possible. This anticoagulation
regimen may also have a reduction of hemorrhagic infarcts [8]. Aspirin
was stopped after 4 weeks, in accordance with the consensus document
[9]. No medication compliance concerns were noted.
2.2. Follow-up
To date, the patient has not experienced any adverse or serious ad-
verse events. Assessments have been made, including clinic visits and
ECGs, in-hospital and at 30, 180 and 270 days post-procedure. TheFig. 2. The ﬁnal result of the deployment of the cobalt chromium alloy COBRA PzF Stent
with Polyzene™-F nano-coating is depicted and full apposition within the vessel is noted.patient has reported a decrease in symptoms and increased physical ac-
tivity has been observed.
3. Discussion
Many clinicians agree that use of a BMS, where possible, limits triple
therapy duration by restricting DAPT to one month [10]. Conversely,
current thinking suggests DES selection increases the duration of triple
therapy to 3–6 months. However, with the use of the COBRA PzF™ Cor-
onary Stent System, DAPT can be limited to onemonth but the resteno-
sis incidence falls in line with a DES.
Stent selection is based on thorough risk assessment of factors each in-
dividual presents, coupled with attributes and characteristics of the
intended stent. Each device has an inherent risk/beneﬁt proﬁle when fac-
toring the best course of action for a particular patient's comorbidities and
anatomy. The decision between implantation of a BMS, DES or, a
bioabsorbable stent, whose scaffold is absorbed after 1–2 years, has in-
cluded a concomitant cocktail of antithrombotic pharmacologic agents
and their respective duration of administration, in the determination.
With its ultra-thin F nano-coating (≤0.05 μm) of Polyzene(TM) on a
cobalt chromium alloy, thin strut stent platform, the COBRA PzF Coro-
nary Stent, designed to provide ﬂexibility, stability and support, offered
the patient described in this report a successful clinical balance of stent
selection and DAPT duration. While the stent coating is approximately
100 times thinner than typical DES coverage, the Polyzene™-F material
has demonstrated decreased platelet adherence and aggregation
[11,12], while decreasing inﬂammation and facilitating re-
endothelialization [13]. In the longer term, the surface material has
been reported to decrease neointimal proliferation, late loss and reste-
nosis rate [13,14,15,16]. Researchers have speculated that albumin's
preferential binding to Polyzene™-F provides favorable conditions for
stent strut endothelialization. This observation is thought to be respon-
sible, in part, for the positive clinical results seen with Polyzene-Fmate-
rial on the Catania™ stent in the ATLANTA and ATLANTA 2 studies that
demonstrated a 3.6% clinically-driven target lesion restenosis rate, with
no deaths, strokes or myocardial infarctions (MIs), in 55 patients and
6.5% all target lesion restenosis rate in 300 patients with 0% late stent
thrombosis (N30 days) recorded at 12 months in both studies [15,16].
With respect to atherothrombotic events, it has been shown that an in-
creased risk of late stent thrombosis is associated with a morphometri-
cally determined ratio, i.e., uncovered to total struts per section [17]. An
optical coherence tomographic comparison, within the same patients,
of stent endothelialization showed greater coverage on the Polyzene-F
coated struts at 7–10 days and at 28–32 days post implantation when
compared to DES and BMS struts and a lower uncovered to total strut
ratio for the Polyzene-F coated stents at all time points, except when it
was not different from the DES struts at the later time point [18,19].
Reduction of antithrombotic medications associated with the use of
the COBRA PzF™ Coronary Stent System, both in the decrease of dura-
tion and elimination of multiple pharmacologic agents can be further
appreciated when reﬂecting on a large scale, nationwide, retrospective
registry on 40,812 patients diagnosedwith a ﬁrst-timeMI [20]. Bleeding
incidence, deﬁned as a hospital admission with a diagnosis of non-fatal
bleeding (primary or secondary) or a diagnosis of bleeding as the cause
of death (fatal bleeding), was 2.6% for the ASA group, 4.6% for
clopidogrel, 4.3% for vitamin K antagonist, 3.7% for ASA plus clopidogrel,
5.1% for ASA plus vitamin K antagonist, 12.3% for clopidogrel plus vita-
min K antagonist, and 12.0% for triple therapy.When the datawere nor-
malized, using aspirin as a reference value of 1, adjusted hazard ratios
for bleeding risk were 1.33 (95% conﬁdence interval 1.11–1.59) for
clopidogrel, 1.23 (0.94–1.61) for vitamin K antagonist, 1.47
(1.28–1.69) for ASA plus clopidogrel, 1.84 (1.51–2.23) for aspirin plus
vitamin K antagonist, 3.52 (2.42–5.11) for clopidogrel plus vitamin K
antagonist, and 4.05 (3.08–5.33) for triple therapy. Selection of the an-
tithrombotic agents, alone and in combination, is clearly an important
consideration in reducing bleeding risk.
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phase III trial, 15,526 patientswithin 7 days of acute coronary syndrome
were randomly assigned (1:1:1) to receive twice daily doses of either
2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months
[21]. Both doses of rivaroxaban reduced the primary efﬁcacy composite
endpoint, death from cardiovascular causes, MI or stroke, as compared
with placebo. However, for subjects with atrial ﬁbrillation, only the
lower dose of rivaroxaban resulted in an increased survival beneﬁt. In
part, this ﬁnding was explained by the authors due to the increase in
fatal bleeding associated with the higher dose of rivaroxaban.
As is typical in patients with signiﬁcant coronary artery disease and
atrial ﬁbrillation, the patient who is the subject of this manuscript was
required to undergo triple therapy, based on her CHA2DS2-VASc score
of 7 and a HAS-BLED score of 4, she was at high risk for embolic and
bleeding events. However the duration of her triple therapy medication
regimentwas limited to onemonth,which lowered the bleeding risk for
this patient. DAPT duration and oral anticoagulation have to be consid-
ered carefully and be as short as possible. The dosages of 2.5mg or 5mg
b.i.d of rivaroxaban are based on theATLAS ACS 2-TIMI 51 trial. This trial
studies patients with ACS and how rivaroxaban reduces cardiovascular
death,MI, or stroke in patients following ACS, and cannot be extrapolat-
ed to patients with atrial ﬁbrillation and stable CAD. The patient in this
manuscript had no ACS, normal renal function and takes NOAC at a dose
of 20 mg daily due to atrial ﬁbrillation.4. Conclusion
Because of anticipated antiplatelet medication risks, patients who
are not DES candidates or who are at particularly high risk for bleeding
events have been targeted initially for treatment with the COBRA PzF
Coronary Stent System. The particular patient described in this report
is an ideal example of the initial intended clinical population for the
COBRA PzF Stent and describes how the new stent design andmaterials
serve this currently unmet clinical need. Because of various comorbid
factors, stent selectionwas critical to the initial and long termclinical re-
sults seen with the COBRA PzF Stent. Planned clinical investigations of
the stent are needed to establish the clinical utility of the device.Sources of funding
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